There are different hurdles with CCL5/CCR5 inhibition in tumor therapy since CCL5 acts as a double-edged sword—initially fueling tumor development but also recruiting antitumor cell populations to the tumor over time [39]. This evidence concerns the gene CCL5 and neoplasm.